Hansa hosts call with distinguished transplant surgeons: Insights on clinical practice and imlifidase Phase 3 Results

/in

Lund, Sweden, 29 October 2025. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA) today announced that it will host a virtual event featuring two distinguished transplant surgeons; Professor Robert Montgomery from NYU Langone Transplant Institute and Professor Matthew Cooper from the Medical College of Wisconsin, to provide deeper insights into the medical journey of highly sensitized […]

Read more

Women in Life Science Denmark (WiLD) expands mentoring program to support next generation of female leaders in life sciences

/in

Third cohort of cross-organizational, high-level mentorship program to commence in November 2025 Continued support from the Lundbeck Foundation and the Novo Nordisk Foundation WiLD celebrates its third anniversary with 250+ members in Denmark 28 October 2025, Denmark: Women in Life Science Denmark (WiLD) today announces that it is launching the third cohort of its successful […]

Read more

Domain Therapeutics Doses First Patients in Phase I / II Trial of DT-7012 Targeting CCR8 in Solid Tumors

/in

DT-7012 is a proprietary, differentiated Treg-depleting anti-CCR8 monoclonal antibody Differentiated binding capacities and competitive properties position it as a promising therapeutic to boost anti-tumor immunity, overcoming immunosuppression Strasbourg, France – Montreal, Canada – Boston, United States, October 28, 2025: Domain Therapeutics ( “Domain” or “the Company” ), the GPCR experts harnessing deep receptor biology to develop […]

Read more

ViCentra Strengthens Leadership Team to Accelerate Growth

/in

Karen Baxter, former VP & GM at Dexcom with deep expertise in diabetes device commercialization across Europe, joins as SVP Sales, Europe Jay Little, leader from Medtronic Diabetes, appointed VP Strategy & Business Development Team expansion will drive growth strategy, market development, and partnerships for scalable expansion to accelerate Kaleido’s growth across European markets Utrecht, […]

Read more

AMS to participate in upcoming investor conferences in November and December

/in

Winsford, UK: Advanced Medical Solutions Group plc (AIM:AMS), the innovative tissue healing medical device company delivering high-performing, cost-effective solutions for better patient outcomes, today announces that the Group will be participating in the following investor conferences in November and December: Read more…

Read more
© Optimum Strategic Communications.